| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 3,076,400 | 2,964,700 | 2,770,200 | 2,771,900 |
| Cost of sales | 414,800 | 407,500 | 363,000 | 392,600 |
| Research and development expenses | 977,700 | 978,400 | 979,700 | 875,900 |
| Acquired in-process research and development expenses | 54,500 | 2,200 | 19,800 | 15,000 |
| Selling, general and administrative expenses | 445,100 | 424,600 | 396,400 | 371,800 |
| Intangible asset impairment charge | 0 | 0 | 379,000 | - |
| Change in fair value of contingent consideration | -1,900 | 900 | 2,200 | 300 |
| Total costs and expenses | 1,890,200 | 1,813,600 | 2,140,100 | 1,655,600 |
| Income (loss) from operations | 1,186,200 | 1,151,100 | 630,100 | 1,116,300 |
| Interest income | 125,700 | 122,400 | 120,900 | 132,200 |
| Interest expense | 3,300 | 3,700 | 3,000 | 7,500 |
| Other expense, net | -9,800 | 13,200 | -17,600 | -16,900 |
| Income (loss) before provision for income taxes | 1,298,800 | 1,283,000 | 730,400 | 1,224,100 |
| Provision for income taxes | 215,900 | 250,100 | 84,100 | 178,700 |
| Net income (loss) | 1,082,900 | 1,032,900 | 646,300 | 1,045,400 |
| Basic (in dollars per share) | 4.24 | 4.02 | 2.52 | 4.05 |
| Basic (in shares) | 255,600,000 | 256,700,000 | 256,900,000 | 258,000,000 |
| Diluted (in dollars per share) | 4.2 | 3.99 | 2.49 | 4.01 |
| Diluted (in shares) | 257,600,000 | 258,900,000 | 259,500,000 | 261,000,000 |
VERTEX PHARMACEUTICALS INC MA (VRTX)
VERTEX PHARMACEUTICALS INC MA (VRTX)